Device
Dynamic contrast-enhanced MRI
Dynamic contrast-enhanced MRI is a medical device with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A1 (100.0%)
Trials by Status
active_not_recruiting133%
recruiting133%
completed133%
Recent Activity
2 active trials
Showing 3 of 3
recruiting
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
NCT03267459
active_not_recruitingnot_applicable
MRI in Diagnosing Solid Tumors of the Eye and Orbit
NCT01653080
completed
Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence
NCT04846257
Clinical Trials (3)
Showing 3 of 3 trials
NCT03267459
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
NCT01653080Not Applicable
MRI in Diagnosing Solid Tumors of the Eye and Orbit
NCT04846257
Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3